Edesa Biotech Free Cash Flow (FCF) History (EDSA)

Edesa Biotech reported −$6.6M in free cash flow for fiscal 2023, an increase of $5.6M from the previous fiscal year.

View full Edesa Biotech company overview

Edesa Biotech free cash flow by year

Edesa Biotech annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20232023-09-30−$6.6M$5.6M
20222022-09-30−$12.3M$1.4M
20212021-09-30−$13.7M−$8.7M
20202020-09-30−$5.0M$7,119−1518.00%
20182018-09-30−$5.0M$4,067
20172017-09-30−$5.0M−$94,482−10004.76%
20162016-09-30−$4.9M−$220,916−385.94%
20152015-09-30−$4.7M−$141,212−617.77%
20142014-08-31−$4.5M−$1.7M−1221.55%
20132013-08-31−$2.8M$1.2M−514.30%
20122012-08-31−$4.0M−1407.48%

Edesa Biotech free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from −$5.0M to −$6.6M, a net decrease of $1.6M. Edesa Biotech's latest reported quarter, Q4 2023, generated −$1.5M in free cash flow, an increase of $4.2M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Edesa Biotech filings at SEC.gov ↗